Study Evaluating Sirolimus in the Treatment of Kidney Transplant

Phase 4 Completed 100 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of this study is to test whether withdrawal of calcineurin inhibitors, followed by treatment with sirolimus, may improve renal function in renal transplant recipients with chronic allograft nephropathy.

Timeline

Start: 2006-08
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sirolimus	Small molecule	—	—

Study Evaluating Sirolimus in the Treatment of Kidney Transplant

Summary

Timeline

Drugs

Indications